Lite Strategy, Inc. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
Lite Strategy, Inc. (LITS) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 2.70% for the 12-month period ending 2018-06-30, per its 10-K filed 2018-08-30.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2018-08-30
- Lite Strategy, Inc. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2018 was 2.70%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2018-06-30 | 2.70% 10-K · filed 2018-08-30 | |
| 2018-05-16 | 2.90% 10-K · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |